Key facts
- GEn1E Lifesciences’s last known valuation is $135.5M (Dec 2025).
- It has raised $25.6M across 2 recorded rounds; the latest was Early Stage VC ($5.5M) in Oct 2025.
- Notable investors include Y Combinator, Khosla Ventures, Gaingels, StartX (US), BoxOne Ventures — 38 tracked in total.
- GEn1E Lifesciences has filed 1 Form D with the SEC, most recently Dec 2022 ($17.0M sold to 89 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 38 names
- ·Watchlist + deal alerts for GEn1E Lifesciences
Funding rounds
2 roundsAbout GEn1E Lifesciences
Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases. The company offers a proprietary drug development model that integrates mechanistic endotyping, kinase modulation, and data-driven clinical insights, enabling researchers and clinicians to accelerate discovery-to-clinic timelines, optimize treatment efficacy, and advance novel therapies for complex diseases.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2018
- Employees
- 6
- Website
- gen1e.com/
- Ownership
- Privately Held (backing)
GEn1E Lifesciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GEn1E Lifesciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GEn1E Lifesciences in its N-PORT filings yet. We sweep new filings monthly.